Apollo Hospitals Enterprise has delivered another robust quarter, with Q4FY26 consolidated PAT rising 36% year‑on‑year to ₹529 crore and revenue up 18% to ₹6,605 crore, according to results reported in late May 2026. EBITDA climbed 31% to ₹1,011 crore, marking healthy operating leverage even after significant investments in Apollo 24/7 and digital health infrastructure.
Financials and dividend
For the full year FY26, the group’s consolidated revenue increased 16% to ₹25,229 crore and PAT surged 34% to ₹1,942 crore, with diluted EPS at ₹134.95. The board has recommended a final dividend of ₹10 per equity share, reinforcing shareholder returns amid a continued expansionary capex cycle.
Across segments, the core hospital business grew 16% YoY in Q4 to ₹3,268 crore with EBITDA margin at 23.9%, while Apollo Health and Lifestyle (AHLL) posted 24% YoY revenue growth and 58% EBITDA growth, turning profitable versus last year’s loss. Apollo HealthCo (digital and omni‑channel pharmacy) delivered 20% YoY revenue growth to ₹2,848 crore and EBITDA of ₹156 crore, more than four times higher than the year‑ago quarter.
Strategic and credit milestones
ICRA has assigned Apollo Hospitals an AAA rating for both long‑term and short‑term borrowings, making it the first Indian hospital‑services company to receive the highest credit rating. Analysts cite the group’s diversified scale, healthy profitability, strong occupancy and resilient demand as key factors behind the upgrade.
Apollo has also consolidated its maternity and fertility footprint by combining Apollo Cradle and Fertility with Cloudnine, creating one of India’s largest integrated mother‑and‑child platforms valued at around ₹1,550 crore via cash and equity, with Apollo Health and Lifestyle becoming the largest non‑financial stakeholder.
Expansion, clinical excellence and international demand
The company continues to expand its pan‑India network, commissioning four new hospitals over the past six months and adding about 855 census beds, with a broader pipeline of roughly 4,400 new beds, including the recently launched 400‑bed Financial District hospital in Hyderabad and the new facility in Sonarpur, Kolkata.
Clinically, Q4 witnessed multiple high‑complexity interventions, from advanced robotic and minimally invasive surgeries to multi‑organ transplant coordination via green corridors across cities such as Chennai, Bengaluru, Hyderabad, Delhi, Navi Mumbai and Lucknow. The International Patient Services division reported strong traction, reinforcing Apollo’s standing as a leading medical‑value‑travel destination from Africa, the Middle East and South‑East Asia.
Digital momentum and outlook
Apollo 24/7 posted a GMV of ₹2,037 crore for FY26, with 26% YoY growth in online pharmacy transactions and expansion of the Apollo Pharmacy network to 7,289 stores, up 663 year‑on‑year. The group also strengthened its payor mix through deeper partnerships with health‑insurance providers and consumer‑driven health‑tech engagement.
With resilient earnings, an AAA credit rating, an expanding asset base and growing clinical and digital scale, Apollo Hospitals is well‑positioned to sustain above‑industry growth while reinforcing its leadership in India’s evolving healthcare landscape.
